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doi:10.1016/j.ejvs.2010.11.012Abstract Aims: Homocysteine upregulates expression of adhesion molecules on endothelial
cells which recruits leukocytes and initiates atherosclerosis. Endothelial cells in hyperhomo-
cysteinemic patients are continuously exposed to high levels of homocysteine. This study
exposed adult endothelial cells and endothelial cells from immune naı¨ve foetal tissue to homo-
cysteine chronically and studied effects on cellular adhesion molecule expression under static
and flow conditions.
Methods: Human umbilical vein endothelial cells (HUVEC) and human saphenous vein endothe-
lial cells (HSVEC) were cultured in medium containing 1 mM DL-homocysteine or L-cysteine for
5e9 days. Proliferation was assessed. Cells were subjected to flowing neutrophils and numbers
of tethered, rolled fixed and transmigrated neutrophils on endothelial cells were counted and
compared to controls. Immunofluorescence staining with antibodies against Intercellular adhe-
sion molecule-1 (ICAM-1), E-selectin and P-selectin were used to quantify expression.
Results: Chronic treatment with 1 mM homocysteine inhibited proliferation of HUVEC and
HSVEC. Homocysteine treated cells showed significantly increased expression of ICAM-1, E-se-
lectin and to a lesser extent P-selectin. In both cell types, homocysteine significantly increased
interactions between neutrophils and endothelial cells under flow conditions (p < 0.05) while
cysteine had no effect.
Conclusion: Endothelial cells from adult and immune naı¨ve foetal tissue showed similar
responses to chronic treatment with homocysteine.
ª 2010 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.74 233570; fax: þ44 1274 309742.
rd.ac.uk (A.M. Graham).
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Atherosclerosis is a chronic inflammatory disease initiated
by endothelial cell (EC) injury. It progresses silently,
producing stratified lesions in arteries leading to acute
events like heart attack or stroke.1 During inflammation,
sequential interactions between leukocytes and EC occur,
mediated by inducible adhesion molecules binding their
ligands. Initial leukocyte contact (tethering) is mainly
mediated by P-selectin on EC and L-selectin on leukocytes
binding their ligands on the opposing cells.2 Subsequently,
tethered leukocytes roll on the EC monolayer, mainly
mediated by E-selectin.3 Subsequently, rolling velocity
decreases, and leukocytes crawl across EC initiating firm
adhesion. These steps are reversible, however, the next
step, diapedesis, is irreversible. In the presence of appro-
priate chemoattractants, like IL-8 and monocyte chemo-
attractant protein-1,4 leukocytes migrate across the
endothelium (Fig. 1).2
Homocysteine (Hcy) is an independent risk factor for
atherosclerosis, a theory first formulated in 1975.5 Up to
40% of patients diagnosed with coronary, or peripheral
atherosclerosis have elevated blood Hcy,1 mostly resulting
from reduced activity or expression of metabolic enzymes.6
Elevated Hcy has also been associated with higher inci-
dences of saphenous vein graft disease following coronary
artery bypass surgery (CABG).7 Hcy involvement in cardio-
vascular disease has recently been explained by several
pathogenic mechanisms including generation of reactive
oxygen species (ROS),8 endoplasmic reticulum stress,6
genetic disruption9 and abnormal fibrinolysis10 and
contributes to smooth muscle cell proliferation, increased
collagen production and platelet aggregation (reviewed
by Lawrence de Koning et al.1). Previous in vitro studies
demonstrated endothelial activation/damage following
incubation with Hcy up to 24 h.11e13 However, acute stim-
ulation cannot accurately reflect a clinically relevant
situation as EC in patients with hyperhomocysteinemia
(hHcy) are continuously exposed to elevated Hcy, which can
modulate EC function. Therefore, in our study human
cultured EC from adult patients (HSVEC), commonly usedFigure 1 Sequential steps in leukocyte emigration through ECs in
antigen, PSGL-1: P-selectin glycoprotein ligand-1, LFA-1: Lymphocy
PECAM-1: Platelet Endothelial Cell Adhesion Molecule.in CABG and foetal source (HUVEC) were exposed to Hcy
for 5e9 days, ensuring each cell cycle stage was exposed
to Hcy. Adhesion molecule expression was determined both
directly (immunofluorescence) and indirectly (real-time
monitoring EC:leukocyte interactions under physiologically
relevant flow conditions). This study aimed to show the
damaging effects of chronic Hcy treatment on human EC
and how this could initiate atherogenesis.
Materials and Methods
Endothelial cell isolation and cell culture
The investigation conforms with principles in the Declara-
tion of Helsinki. Human umbilical vein endothelial cells
(HUVEC) were isolated with consent of the local ethical
board (LERC NO: 03/12/433) using an enzymatic technique,
already described.14 Human saphenous vein endothelial
cells (HSVEC) were isolated in the same way. The endo-
thelial phenotype was confirmed using phase-contrast
microscopy, immunostaining for von Willebrand factor and
CD31 (PECAM-1: platelet endothelial cell adhesion mole-
cule-1) and cobblestone morphology of confluent cells.
Neutrophil isolation
Whole blood was obtained from consented healthy donors
according to regulations of the University of Bradford into
0.1 M sodium citrate (1:10), mixed with an equal volume of
0.08 M dextran and 0.025 M HEPES in HBSS (Hanks Balanced
Salt Solution) then sedimented at room temperature.
Neutrophils were separated by centrifugation on Lympho-
prep as previously described16 and neutrophil concentra-
tion adjusted as required.
EC incubation with Hcy
Individual donor HSVEC or HUVEC were cultured between
5 and 9 days in complete medium containing either 1 mM
DL-Hcy, 1 mM L-cysteine (L-Cys) or complete media aloneinflammation showing key CAM in each step. VLA-4: very late
te function-associated antigen 1, Mac-1: Macrophage antigen-1,
Figure 2 Effects of DL-Hcy on HSVEC:neutrophil interactions.
HSVEC were stimulated with DL-Hcy (1 mM; 5e9 days) or
histamine (105 M, 18 min) or TNF-a (120 U/ml; 4 h or 24 h) as
positive controls for tethering (P-selectin), rolling (E-selectin)
and adhesion (ICAM-1) respectively. Effects on HSVEC:neu-
trophil interactions under flow conditions were quantified.
Non-treated HSVEC from the same patient were used in each
experiment as controls. Results are expressed as mean (SD)
from 5 donors (nZ 5). )P < 0.001 for positive versus negative
control cells, ))P < 0.001 for DL-Hcy versus control cells.
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(passage 3e6) were plated as described below for
experiments.
Quantification of cell proliferation rate
HUVEC and HSVEC proliferation was determined following
seeding into 96 well plates (1  104 cells/well) for 96 h.
Subsequently Methylthiazolyldiphenyl-tetrazolium bromide
(MTT) solution (5 mg/ml; 3e4 h) was added at 1:10 v/v with
culture volume. Media was discarded and crystals formed
dissolved in DMSO in a volume equal to the original culture
and absorbancemeasured usingmicroplate reader (570 nm).Table 1 Numbers of interactions of control, DL-Hcy and L-Cys tre
indicated for each treatment.
1Y tethering 2Y tethering
Control 12 0
Control 0 0
Control 84 84
Control 312 132
Control 64 28
Control mean þ SD 94  127 49  58
DL-Hcy 246 234
DL-Hcy 588 384
DL-Hcy 288 156
DL-Hcy 684 312
DL-Hcy 192 360
DL-Hcy mean þ SD 388  230 289  94
L-Cys 24 12
L-Cys 36 0
L-Cys 144 60
L-Cys 96 12
L-Cys 122 72
L-Cys mean þ SD 84  53 31  32Effects of homocysteine on EC: neutrophil
interactions
Confluent monolayers of HUVEC or HSVEC exposed to Hcy
on 35 mm dishes were subjected to laminar fluid shear
stress in a Glycotech flow chamber. Live time microscopic
observation of EC exposed to flow as previously described14
was carried out using an inverted microscope. Shear stress
was applied by perfusing carrier medium containing
neutrophils (1  106 cells/ml) at 0.5 ml/min, equivalent to
shear stress 1.1 dyn/cm2 and recorded for 14 min (supple-
mental movie). Cellular interactions were quantified as
primary and secondary tethering, rolling, firm adhesion
and transmigration following manual counting and results
presented graphically using means of each type of inter-
action from individual experiments SD.
Specific blocking antibodies were used to determine
CAM roles in mediating different EC:neutrophil interac-
tions. Mouse monoclonal blocking antibodies against ICAM-
1, E-selectin and P-selectin and the negative control anti-
body (mouse IgG1) as used in control experiments were
from R&D Systems, Oxon, UK. Cell:cell interactions were
counted manually and results presented graphically using
means of each type of interaction from individual experi-
ments SD.
Effects of Hcy incubation on HUVEC and HSVEC
adhesion molecule expression by
immunofluorescent staining
Confluent monolayers of HUVEC and HSVEC in chamber
slides exposed to Hcy as described previously, were fixed at
20 C in 100% methanol (10 min), then washed with PBS.
Cells were blocked with 10% donkey serum (SigmaeAldrich)
for 90 min, then incubated with mouse monoclonal anti
human E-Selectin/CD62E FITC (1:25), anti human P-Selec-
tin/CD62P FITC (1:25) or anti human ICAM-1/CD54 FITCated HUVEC in individual experiments (nZ 5). Mean  SD are
Rolling Fixed (adhered) Transmigrated
0 0 4
0 2 2
84 48 36
96 12 24
80 32 32
52  48 19  21 20  16
1173 1262 1564
720 688 1508
508 336 936
144 48 228
492 1664 2028
800  662 607  378 1253  692
16 0 32
12 0 24
96 48 120
24 12 36
168 132 132
63  68 38  56 69  53
Table 2 Mean different EC:neutrophil interactions and p values of differences between different treatments.
HUVEC HSVEC
Non-treated DL-Hcy Cys Non-treated DL-Hcy Positive control
Primary tethering 94 388* 84** 25 172y 319yy
Secondary tethering 49 289* 31** 17 152y 242yy
Rolling 19 800* 38** 6 251y 329yy
Fixed 52 607* 63** 19 161y 307yy
Transmigration 20 1253* 69** 3 47y 143yy
*p < 0.05 for DL-Hcy versus non-treated, **p < 0.05 for DL-Hcy versus Cys, yp < 0.001 for DL-Hcy versus non-treated, yyp < 0.001 for DL-Hcy
versus Cys.
Figure 3 Blocking antibody effects on DL-Hcy induced
HSVEC:neutrophil interactions. HSVEC were stimulated with DL-
Hcy (1 mM; 6e9 days) and incubated with a blocking antibody
for P-selectin (A), E-selectin (B) or ICAM-1 (C) for 30min prior to
flow. HSVEC:neutrophil interactions -tethering, rolling, adhe-
sion (fixed) and transmigration, under flow conditions were
quantified. Non-treated HSVEC from the same donor were used
in each experiment as controls. Antibody specificity was
confirmed by incubation of non-treated HSVEC with irrelevant
isotype control antibody (IgG1). Results are expressed as mean
(SD) from 5 donors (nZ 5). Asterisk: ()) P < 0.001 for DL-Hcy
versus (DL-Hcy þ blocking Ab).
432 K. Alkhoury et al.(1:37) overnight at 4 C (all antibodies, R&D Systems) and
DAPI counterstained the nuclei. Cells were viewed on an
Eclipse TE2000 inverted research microscope (Nikon,
Tokyo, Japan) and digitally photographed (Hamamatsu,
Japan) using 20 objective. Photos of four randomly chosen
fields from each experiment using the FITC-filter and
DAPI-filter were quantified using ImageJ software after
adjusting the threshold. DAPI counterstained nuclei images
ensured equal numbers of cells in each chosen field,
therefore differences between FITC filter-captured photos
were not due to different cellular density.
Statistical analysis
SPSS package was used to analyse data using a paired
Student’s t-test and results were presented as mean  SD
with differences considered significant when p  0.05.
Results
Chronic exposure of human EC to Hcy attenuates
cellular proliferation
Chronic exposure to 1 mM DL-Hcy significantly decreased
HUVEC proliferation compared to non-treated control
HUVEC both by MTT assay (p < 0.01) and manual hemocy-
tometer counting demonstrating a 15% reduction in cell
numbers in flasks treated chronically with DL-Hcy. Exposure
to 1 mM L-Cys also showed some decrease in HUVEC
proliferation rate (not statistically significant). Similar data
was obtained using HSVEC (data not shown).
Cell viability as determined by Trypan Blue exclusion
was not significantly decreased by DL-Hcy exposure (95%
viability of DL-Hcy-treated cells versus 97% viability of non-
treated and Cys-treated cells).
Effects of chronic exposure to Hcy on
EC:neutrophil interactions under flow conditions
Interactions of HSVEC and HUVEC with neutrophils in
control cells were low confirming no activation under flow,
while cells exposed to 1 mM DL-Hcy showed significantly
increased interactions. Primary and secondary tethering
were significantly increased 7- and 9-fold respectively
(p < 0.001, n Z 5) for HSVEC and increased 4- and 6-fold
respectively (p < 0.05, n Z 5) for HUVEC. Rolling interac-
tions, fixed (adherent) and transmigrated neutrophils
Endothelial Cell Activation Following Chronic Homocysteine Treatment 433increased 41-, 9- and 15-fold respectively (p < 0.001
throughout, n Z 5) after treatment with 1 mM DL-Hcy in
HSVEC, while interactions were increased 43-, 12- and 64-
fold respectively (p < 0.05 throughout, n Z 5) in HUVEC
(Fig. 2; Tables 1 & 2). Histamine (105 M; 18 min) as positive
control showed 13- and 14-fold increase in primary and
secondary tethering respectively. TNF-a (120 U/ml; 4 h),
positive control for neutrophil rolling showed 53-fold
increased interactions. For fixed and transmigrated
neutrophils, TNF-a (120 U/ml; 24 h) as positive control
showed 17- and 46-fold increased interactions respectively
(n Z 5). All increases were compared to non-treated
cells (Table 2). Interactions on incubation with 1 mM L-Cys
were comparable to non-treated cells (data not shown).Effects of chronic Hcy exposure on expression of
CAM in EC
Effects of specific blocking antibodies against P-selectin,
E-selectin and ICAM-1 on DL-Hcy-exposed HSVEC:neutrophilFigure 4 DL-Hcy effects on CAM expression. Confluent HUVEC from
F: DL-Hcy 1 mM; 5e9 days. Cells in A and D were incubated with mon
human ICAM-1/CD54 FITC; cells in C and F with human P-Selectin/C
ImageJ software. Results are expressed as mean (SD) from 6 to 8
cells.interactions are shown in Fig. 3 (nZ 5). DL-Hcy significantly
increased interactions as described above. Addition of
a specific P-selectin blocking antibody prior to flow signifi-
cantly reduced primary and secondary tethering (p < 0.001)
compared to DL-Hcy alone, without affecting other interac-
tions (Fig. 3A). A specific E-selectin blocking antibody
prior to flow significantly reduced DL-Hcy-mediated rolling
(p < 0.001) without affecting tethering, firm adhesion or
transmigration (Fig. 3B). A specific ICAM-1 blocking antibody
prior to flow significantly reduced fixed and transmigration
interactions (p < 0.001) without reducing tethering or
rolling in response to DL-Hcy (Fig. 3C). Incubation with iso-
type control IgG antibodies in control experiments showed
comparable interactions to non-treated control cells (data
not shown). Similar data was obtained in HUVEC (data not
shown).
Direct expression of ICAM-1, E-selectin and P-selectin
determined by immunostaining of HUVEC with FITC-tagged
antibodies against each CAM showed DL-Hcy induced
expression of all three CAM in HUVEC (Fig. 4DeF) compared
to non-treated cells (Fig. 4AeC) or Cys-treated cells (datasame donor were treated: A, B and C: no treatment, D, E and
oclonal anti human E-Selectin/CD62E FITC; cells in B and E with
D62P FITC. Immunofluorescence images were quantified using
different donors (nZ 6e8). )P < 0.05 for DL-Hcy versus control
434 K. Alkhoury et al.not shown). Cells stimulatedwith histamine (105M; 18min),
TNF-a (120 U/ml; 4 h) or TNF-a (120 U/ml; 24 h) as positive
controls confirmed induced expression of P-selectin,
E-selectin and ICAM-1 respectively (data not shown).
Quantification showed DL-Hcy induced significant (2.5 fold)
up-regulation of E-selectin and ICAM-1 compared to non-
treated cells (p < 0.05; Fig. 4; n Z 6e8). However, the
increase in P-selectin expression in DL-Hcy-treated cells over
non-treated cells (1.5 fold) was not significant (n Z 8).
Similar results were obtained in HSVEC (data not shown).Discussion
Hcy has been a suggested atherosclerotic risk factor for
several decades.5 Failure of recent clinical trials of vitamin
based lowering of plasma Hcy to reduce cardiovascular
risk15 may be attributed to complex metabolic networks
involving homocysteine and vitamins.16 Abundant evidence
exists in vitro16e18 and in vivo19 for acute Hcy mediated
damage of EC as a key primary event in accelerated
atherogenesis. Published in vitro studies using various EC
have addressed acute mechanisms of damage (less than
48 h Hcy17,20). This study used EC from different human
vascular beds to study inflammatory responses to chronic
Hcy treatment (5e9 days). HSVEC, from saphenous vein,
represent adult ECs commonly used in CABG, and can
develop post operative graft disease while HUVEC, from
umbilical cord, are immature cells and may respond in
a less clinically relevant way.21 Although Hcy concentra-
tions in clinical studies are lower than those used to treat
cultured cells, in culture cells are resistant to stress
conditions compared to in vivo.22 Our study used the only
commercially available Hcy, a racemic D/L mixture, making
the active Hcy concentration 0.5 mM, similar to concen-
trations in patients with homozygous CBS deficiency.6
DL-Hcy up to 5 mM did not cause HSVEC death in our labo-
ratory (unpublished). We show DL-Hcy (1 mM, 5e9 days) did
not reduce HUVEC or HSVEC viability (>95% in all cases) in
agreement with previous acute in vitro work23 but did
significantly reduce growth rate as previously observed 2.24
This contrasted to Lee’s group25 where Hcy induced dose-
dependent HUVEC apoptosis. Possibly conditions such as
media growth factors, or passage number increased sensi-
tivity to apoptosis in that study.
Neutrophils, representing approximately 60% of leuko-
cytes, are widely used in vitro to study inflammatory
responses.26 Neutrophil adhesion to EC, vital in acute
inflammation, is also important in early atherosclerotic
lesion development.27 While it is accepted that monocyte
and lymphocyte adhesion to EC is vital in fatty streak
formation, this study focuses on both the role of Hcy in
atherosclerosis initiation and damage to HSVEC in graft vein
disease making neutrophils appropriate for this in vitro
model. Fig. 2 and Table 1 demonstrate that Hcy induced
EC:neutrophil interactions in HUVEC and HSVEC under flow,
significantly increasing all interactions (Table 2). Previous
publications show tethering is P-selectin mediated, rolling is
via E-selectin and firm adhesion (indicated as fixed in results)
and transmigration are via ICAM-1 (Fig. 1, reviewed by Muller
et al.2). VCAM-1 is only involved in monocyte recruitment
and therefore was not quantified.28Up-regulation of CAM expression in both HSVEC and
HUVEC in response to chronic Hcy treatment was also
confirmed both under flow (by co-incubation with block-
ing antibodies) and by direct immunofluorescence.
Although the limit of detection of immunofluorescence
could not confirm increased P-selectin expression, the
significant increased tethering induced by Hcy, and
reversal by a P-selectin blocking antibody, confirmed
a role for P-selectin. Sparse expression of P-selectin
(<10,000 molecules/cell) on activated EC may explain
ours and others failure to detect this CAM.29 1 mM L-Cys
did not induce CAM in HSVEC or HUVEC suggesting acti-
vatory effects are specific to Hcy and not due to osmotic
or non-specific effects resulting from the amino acid
concentration used, or the free thiol group. Detection of
CAM following acute Hcy has produced conflicting results
with no induction quantified, despite increased adhesion
under static conditions and in rats in vivo.20 However,
induced expression of P-selectin, E-selectin and ICAM-
118,30 on mouse and human EC in other publications
support our data. Some authors suggest Hcy adhesion
molecule induction is transient, peaking at 6 h, but our
study clearly demonstrates chronic exposure causes
continuous up-regulation of P-selectin, E-selectin and
ICAM-1 in human adult as well as immature cultured EC.
Some investigators have argued that HUVEC is
a misleading model for studying vascular diseases21. Our
study shows HSVEC, cells at risk of host graft vein disease
following CABG and more representative of cells under-
going damage in diseased adults are activated by Hcy in
addition to HUVEC. Therefore our data shows Hcy
induced significant inflammatory responses in both cell
types and may explain the increased risk of saphenous
vein graft disease in hHcy patients following CABG.7
HUVEC demonstrated higher quantifiable interactions
compared to HSVEC in accordance with previously pub-
lished treatment of HUVEC with pro-inflammatory cyto-
kines21 which may reflect increased basal reactivity. Thus
action is required when HUVEC are used to model
inflammation.
In summary, chronic exposure of adult and foetal human
EC to Hcy upregulates CAM that mediate leukocyte diape-
desis important in chronic inflammation, a vital step in
atherosclerotic lesion development. Molecular mechanisms
are currently under investigation.Conflict of Interest
None.Funding
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Appendix. Supplementary material
The supplementary data associated with this article can be
found in the on-line version, at doi:10.1016/j.ejvs.2010.11.
012.
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